Your browser is no longer supported. Please, upgrade your browser.
Ocuphire Pharma, Inc.
Index- P/E- EPS (ttm)-6.29 Insider Own0.40% Shs Outstand16.93M Perf Week23.58%
Market Cap72.78M Forward P/E- EPS next Y-1.34 Insider Trans107.25% Shs Float14.97M Perf Month9.02%
Income-67.70M PEG- EPS next Q-0.45 Inst Own15.10% Short Float2.97% Perf Quarter-4.61%
Sales0.10M P/S727.75 EPS this Y39.40% Inst Trans31.90% Short Ratio0.29 Perf Half Y-4.19%
Book/sh1.22 P/B3.57 EPS next Y66.10% ROA- Target Price23.00 Perf Year-30.06%
Cash/sh1.36 P/C3.21 EPS next 5Y- ROE- 52W Range3.35 - 13.81 Perf YTD-32.97%
Dividend- P/FCF- EPS past 5Y32.60% ROI- 52W High-68.51% Beta0.14
Dividend %- Quick Ratio8.80 Sales past 5Y- Gross Margin- 52W Low29.85% ATR0.38
Employees5 Current Ratio8.80 Sales Q/Q- Oper. Margin- RSI (14)57.78 Volatility14.88% 8.04%
OptionableYes Debt/Eq0.00 EPS Q/Q81.10% Profit Margin- Rel Volume4.21 Prev Close4.14
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.56M Price4.35
Recom1.70 SMA2010.01% SMA50-1.00% SMA200-19.01% Volume6,576,214 Change5.20%
Nov-23-21 09:00AM  
Nov-15-21 01:32PM  
Nov-12-21 07:00AM  
Nov-01-21 09:30AM  
Oct-07-21 07:00AM  
Oct-01-21 08:49AM  
Sep-27-21 07:00AM  
Sep-03-21 05:00PM  
Sep-02-21 07:00AM  
Aug-12-21 07:00AM  
Aug-09-21 08:35AM  
Aug-06-21 07:30AM  
Jul-22-21 08:00AM  
Jul-13-21 09:00AM  
Jul-09-21 05:00PM  
Jun-30-21 07:15AM  
Jun-20-21 03:27AM  
Jun-17-21 09:15AM  
Jun-11-21 07:30AM  
Jun-08-21 04:10PM  
Jun-04-21 09:04AM  
May-20-21 07:30AM  
May-18-21 07:30AM  
May-13-21 11:15AM  
May-12-21 07:30AM  
May-07-21 08:00AM  
Apr-22-21 08:00AM  
Apr-08-21 08:31AM  
Apr-01-21 05:10PM  
Mar-15-21 06:00AM  
Mar-10-21 04:30PM  
Mar-05-21 08:44AM  
Mar-04-21 08:27AM  
Feb-18-21 08:53AM  
Feb-11-21 09:13AM  
Feb-08-21 07:55AM  
Jan-20-21 07:00AM  
Jan-06-21 07:00AM  
Jan-05-21 07:00AM  
Dec-30-20 08:30AM  
Dec-08-20 07:00AM  
Nov-19-20 07:00AM  
Nov-16-20 06:00AM  
Nov-12-20 06:00AM  
Nov-10-20 10:09AM  
Nov-09-20 09:00AM  
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of various eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances, and pharmacologically induced mydriasis, as well as that is in Phase II clinical trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MANUSO JAMES S JDirectorNov 18Buy3.502,0007,00016,570Nov 22 04:01 PM
Pepose JayDirectorSep 13Buy4.7512,63159,99714,744Sep 15 08:00 AM
Benton SusanDirectorSep 02Buy4.5720,00091,40023,976Sep 03 04:02 PM